NEW YORK, NY / ACCESSWIRE / July 5, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Arqit Quantum Inc. f/k/a Centricus Acquisition Corp. (NASDAQ:ARQQ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/arqit-quantum-inc-f-k-a-centricus-acquisition-corp-loss-submission-form?prid=29535&wire=1
Lead Plaintiff Deadline: July 5, 2022
This lawsuit is on behalf of: (i) all persons or entities who purchased or otherwise acquired Arqit securities between September 7, 2021 and April 18, 2022, inclusive; and/or (ii) all holders of Centricus securities as of the record date for the special meeting of shareholders held on August 31, 2021 to consider approval of the merger between Arqit and Centricus (the “Merger”) and entitled to vote on the Merger.
Allegations against ARQQ include that: (1) Arqit’s proposed encryption technology would require widespread adoption of new protocols and standards for telecommunications; (2) British cybersecurity officials questioned the viability of Arqit’s proposed encryption technology in a meeting in 2020; (3) the British government was not an Arqit customer but, rather, providing grants to Arqit; (4) Arqit had little more than an early-stage prototype of its encryption system at the time of the Merger; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Pegasystems Inc. (NASDAQ:PEGA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/pegasystems-inc-loss-submission-form?prid=29535&wire=1
Lead Plaintiff Deadline: July 18, 2022
This lawsuit is on behalf of all persons and entities that purchased PEGA common stock between May 29, 2020 and May 9, 2022, inclusive.
Allegations against PEGA include that: (1) PEGA had engaged in corporate espionage and misappropriation of trade secrets to better compete against Appian, a principal competitor; (2) defendants’ product development and associated success was, in significant part, not the result of its own research and product testing but rather the result of such corporate espionage and trade secret theft; (3) defendants had engaged in a scheme to steal Appian trade secrets, which was not only known to, but carried out through, the personal involvement of the Company’s CEO; (4) the Company’s CEO and other officers and employees did not comply with the Company’s written Code of Conduct, including its express prohibition on “stealing” confidential information from a competitor and “misrepresenting your identity in hopes of obtaining confidential information”; (5) the Company was “unable to reasonably estimate damages” in the lawsuit filed by Appian as a result of the foregoing misconduct (the “Appian Litigation”); and (6) as a result of the foregoing, defendants’ statements about PEGA’s business, operations, prospects, legal compliance, and potential damages exposure in the Appian Litigation were materially false and/or misleading and/or lacked a reasonable basis when made.
CareDx, Inc. (NASDAQ:CDNA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/caredx-inc-loss-submission-form?prid=29535&wire=1
Lead Plaintiff Deadline: July 22, 2022
This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.
Allegations against CDNA include that: (1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company’s RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company’s testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE : The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/707561/SHAREHOLDER-ALERT-ARQQ-PEGA-CDNA-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
